Krsnaa Diagnostics Limited (KRSNAA.NS)
INR 910.0
(-0.9%)
INR 910.0
(-0.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.61 Billion INR | 1.81% |
| 2022 | 1.41 Billion INR | -2.3% |
| 2021 | 1.46 Billion INR | 37.4% |
| 2020 | 3.58 Billion INR | 42.05% |
| 2019 | -1.01 Billion INR | 25.11% |
| 2018 | -325.17 Million INR | 84.47% |
| 2017 | 317.99 Million INR | 122.3% |
| 2016 | 144.81 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 539.94 Million INR | 8.02% |
| 2024 Q1 | 426.68 Million INR | 4.05% |
| 2023 Q3 | 414.71 Million INR | 15.37% |
| 2023 Q4 | 437.02 Million INR | 5.38% |
| 2023 FY | - INR | 1.81% |
| 2023 Q1 | 355.87 Million INR | -11.94% |
| 2023 Q2 | 359.46 Million INR | 1.01% |
| 2022 Q1 | 324.26 Million INR | 6.3% |
| 2022 Q4 | 404.11 Million INR | 19.03% |
| 2022 FY | - INR | -2.3% |
| 2022 Q3 | 339.51 Million INR | -2.7% |
| 2022 Q2 | 348.93 Million INR | 7.61% |
| 2021 Q1 | 447.44 Million INR | 33.4% |
| 2021 FY | - INR | 37.4% |
| 2021 Q4 | 305.04 Million INR | -11.19% |
| 2021 Q3 | 343.46 Million INR | -2.33% |
| 2021 Q2 | 351.66 Million INR | -21.41% |
| 2020 FY | - INR | 42.05% |
| 2020 Q4 | 335.42 Million INR | 0.0% |
| 2019 FY | - INR | 25.11% |
| 2019 Q4 | 175.02 Million INR | 0.0% |
| 2018 FY | - INR | 84.47% |
| 2017 FY | - INR | 122.3% |
| 2016 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dr. Lal PathLabs Limited | 6.78 Billion INR | 76.253% |
| Metropolis Healthcare Limited | 2.96 Billion INR | 45.776% |
| Thyrocare Technologies Limited | 1.48 Billion INR | -8.717% |
| Vijaya Diagnostic Centre Limited | 2.2 Billion INR | 27.097% |
| Vimta Labs Limited | 878.1 Million INR | -83.398% |